Literature DB >> 22042085

HBcAg induces PD-1 upregulation on CD4+T cells through activation of JNK, ERK and PI3K/AKT pathways in chronic hepatitis-B-infected patients.

Man Li1, Xue-Hua Sun, Xiao-Jun Zhu, Shu-Gen Jin, Zhen-Jun Zeng, Zhen-Hua Zhou, Zhuo Yu, Yue-Qiu Gao.   

Abstract

Hyper-expression of programmed death-1 (PD-1) is a hallmark of exhausted T cells. In chronic hepatitis-B virus (HBV)-infected patients, PD-1 upregulation on T cells was often observed. The mechanism of it has not been fully understood. In this study, we examined the dynamic changes of PD-1 expression on T cells during the natural history of chronic HBV infection and explored the signaling pathway of PD-1 upregulation by the hepatitis-B core antigen (HBcAg). Sixty-seven chronic HBV-infected patients were categorized into an immune tolerance group, an immune clearance group and an inactive virus carrier group, and 20 healthy volunteers were chosen as normal control group. Peripheral blood mononuclear cells from patients and healthy volunteers, and T lymphocytes from healthy volunteers were separated. Results showed that the PD-1 expression level on CD4(+)T cells in every phase of chronic HBV infection was significantly higher than that in healthy volunteers, whereas such effects were not observed on CD8(+)T cells. In the immune clearance phase, a positive correlation was found between serum HBV DNA level and the PD-1 expression level on CD4(+)T cells. In all phases, no correlation was shown between serum alanine amino transferase (ALT) level and PD-1 expression level. Phosphorylation of JNK, ERK and AKT was induced by HBcAg, and inhibitors of JNK, ERK and PI3K/AKT significantly decreased the HBcAg-induced PD-1 upregulation on CD4(+)T cells. In conclusion, the PD-1 expression level on CD4(+)T cells was upregulated in every phase of chronic HBV infection, which was induced by HBcAg through JNK, ERK and PI3K/AKT signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22042085     DOI: 10.1038/labinvest.2011.157

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  11 in total

1.  HoxA10 Facilitates SHP-1-Catalyzed Dephosphorylation of p38 MAPK/STAT3 To Repress Hepatitis B Virus Replication by a Feedback Regulatory Mechanism.

Authors:  Qingyu Yang; Qi Zhang; Xuewu Zhang; Lei You; Wenbiao Wang; Weiyong Liu; Yang Han; Chunqiang Ma; Wei Xu; Junbo Chen; Hua Yang; Pin Wan; Yao Zhou; Yingle Liu; Kailang Wu; Ziwen Yang; Jianguo Wu
Journal:  J Virol       Date:  2019-03-21       Impact factor: 5.103

2.  Hepatitis B core antigen upregulates B7-H1 on dendritic cells by activating the AKT/ERK/P38 pathway: a possible mechanism of hepatitis B virus persistence.

Authors:  Man Li; Zhen-Hua Zhou; Xue-Hua Sun; Xin Zhang; Xiao-Jun Zhu; Shu-Gen Jin; Ya-Ting Gao; Yun Jiang; Yue-Qiu Gao
Journal:  Lab Invest       Date:  2016-09-12       Impact factor: 5.662

3.  The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.

Authors:  Davide Brusa; Sara Serra; Marta Coscia; Davide Rossi; Giovanni D'Arena; Luca Laurenti; Ozren Jaksic; Giorgio Fedele; Giorgio Inghirami; Gianluca Gaidano; Fabio Malavasi; Silvia Deaglio
Journal:  Haematologica       Date:  2013-01-08       Impact factor: 9.941

4.  microRNA-4717 differentially interacts with its polymorphic target in the PD1 3' untranslated region: A mechanism for regulating PD-1 expression and function in HBV-associated liver diseases.

Authors:  Guoyu Zhang; Na Li; Zhu Li; Qianqian Zhu; Fang Li; Cuiling Yang; Qunying Han; Yi Lv; Zhihua Zhou; Zhengwen Liu
Journal:  Oncotarget       Date:  2015-08-07

5.  Attenuation of lymphocyte immune responses during Mycobacterium avium complex-induced lung disease due to increasing expression of programmed death-1 on lymphocytes.

Authors:  Chin-Chung Shu; Jann-Yuan Wang; Ming-Fang Wu; Chen-Tu Wu; Hsin-Chih Lai; Li-Na Lee; Bor-Luen Chiang; Chong-Jen Yu
Journal:  Sci Rep       Date:  2017-02-07       Impact factor: 4.379

6.  T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers.

Authors:  Marzia Palma; Giusy Gentilcore; Kia Heimersson; Fariba Mozaffari; Barbro Näsman-Glaser; Emma Young; Richard Rosenquist; Lotta Hansson; Anders Österborg; Håkan Mellstedt
Journal:  Haematologica       Date:  2016-12-07       Impact factor: 9.941

Review 7.  CTLA‑4 interferes with the HBV‑specific T cell immune response (Review).

Authors:  Hui Cao; Ruiwen Zhang; Wei Zhang
Journal:  Int J Mol Med       Date:  2018-05-17       Impact factor: 4.101

8.  HBV and HIV/HBV Infected Patients Have Distinct Immune Exhaustion and Apoptotic Serum Biomarker Profiles.

Authors:  Mohamed Tarek M Shata; Enass A Abdel-Hameed; Susan D Rouster; Li Yu; Meina Liang; Esther Song; Mark T Esser; Norah Shire; Kenneth E Sherman
Journal:  Pathog Immun       Date:  2019-02-13

9.  CD28 family of receptors on T cells in chronic HBV infection: Expression characteristics, clinical significance and correlations with PD-1 blockade.

Authors:  Zong-Sheng Tang; You-Hua Hao; E-Juan Zhang; Chun-Li Xu; Yun Zhou; Xin Zheng; Dong-Liang Yang
Journal:  Mol Med Rep       Date:  2016-06-13       Impact factor: 2.952

10.  HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?

Authors:  Elisa Gremese; Antonio Gasbarrini; Gianfranco Ferraccioli
Journal:  RMD Open       Date:  2020-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.